Designing Cardiovascular Outcomes Trials in Clonal Hematopoiesis of Indeterminate Potential

Designing cardiovascular outcomes trials in CHIP will require moving beyond a 1-size-fits-all approach toward genotype-informed, mechanism-driven trial frameworks. Leveraging innovative trial designs, integrating CHIP analyses into ongoing cardiovascular trials, and fostering interdisciplinary multicenter collaboration will accelerate translating CHIP biology into effective cardiovascular therapies. Establishing an evidence base for managing CHIP-associated cardiovascular risk represents a critical and timely priority for precision cardiovascular medicine.

Corresponding Author: Peter Libby, MD, Heart and Vascular Institute, Center of Excellence in Vascular Biology and Center for Inflammation Imaging at Mass General Brigham Hospital and the Harvard Medical School, 77 Avenue Louis Pasteur, NRB 741, Boston, MA 02115-6110 (plibby@bwh.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.